Why the market will watch Calluna Pharma’s CAL101 more closely after AURORA enrollment ends ahead of plan
Calluna Pharma finished Phase 2 AURORA enrollment early for CAL101 in IPF. Read what this means for fibrosis competition and Q1 2027 data.
Pharma & Biotech